Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
18.10 USD   -2.53%
09/12Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains Neutral Rating
MT
09/12SVB Securities Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $21, Maintains Outperform Rating
MT
09/12HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $20, Reiterates Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Analyst Recommendations on DECIPHERA PHARMACEUTICALS, INC.
09/12Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains ..
MT
09/12SVB Securities Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $21, Maintai..
MT
09/12HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $20, Reiterat..
MT
08/29Cowen Starts Deciphera Pharmaceuticals at Outperform With $25 Price Target
MT
08/05HC Wainwright Adjusts Price Target on Deciphera Pharmaceuticals to $20 From $15, Reiter..
MT
08/05JMP Securities Upgrades Deciphera Pharmaceuticals to Market Outperform From Market Perf..
MT
08/04Piper Sandler Adjusts Deciphera Pharmaceuticals Price Target to $13 From $11, Maintains..
MT
04/13Truist Securities Adjusts Deciphera Pharmaceuticals' Price Target to $11 from $10, Keep..
MT
02/28Barclays Cuts Deciphera Pharmaceuticals to Underweight From Equalweight, Price Target t..
MT
2021Piper Sandler Adjusts Deciphera Pharmaceuticals' Price Target to $11 From $14, Maintain..
MT
2021HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $15 From $25, Reiterat..
MT
2021JPMorgan Adjusts Price Target on Deciphera Pharmaceuticals to $10 From $43, Maintains N..
MT
2021Barclays Downgrades Deciphera Pharmaceuticals to Equal-Weight Rating From Overweight, A..
MT
2021HC Wainwright Adjusts Price Target on Deciphera Pharmaceuticals to $25 from $70, Keeps ..
MT
2021Canaccord Genuity Downgrades Deciphera Pharmaceuticals to Hold From Buy; Price Target i..
MT
2021Barclays Lowers Deciphera Pharmaceuticals to Equal-Weight From Overweight, Price Target..
MT
2021Stifel Downgrades Deciphera Pharmaceuticals to Hold From Buy; Price Target is $10
MT
2021Jones Trading Double Downgrades Deciphera Pharmaceuticals to Sell from Buy, Adjusts PT ..
MT
2021Truist Securities Downgrades Deciphera Pharmaceuticals to Hold from Buy, Adjusts PT to ..
MT
2021JMP Securities Adjusts Deciphera Pharmaceuticals' Price Target to $64 from $70, Keeps M..
MT
2021Guggenheim Downgrades Deciphera Pharmaceuticals to Neutral From Buy, Removes $60 PT
MT
2021DECIPHERA PHARMACEUTICALS : Truist Securities Adjusts Deciphera Pharmaceuticals PT to $65 ..
MT
2021DECIPHERA PHARMACEUTICALS : Stifel Resumes Deciphera Pharmaceuticals at Buy with $60 Price..
MT
2021DECIPHERA PHARMACEUTICALS : HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target ..
MT
2021DECIPHERA PHARMACEUTICALS : Barclays Adjusts Price Target on Deciphera Pharmaceuticals to ..
MT
2021DECIPHERA PHARMACEUTICALS : Piper Sandler Adjusts Price Target on Deciphera Pharmaceutical..
MT
2021DECIPHERA PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Deciphera Pharmaceutical..
MT
2021DECIPHERA PHARMACEUTICALS : Credit Suisse Starts Deciphera Pharmaceuticals at Outperform w..
MT
2021DECIPHERA PHARMACEUTICALS : Credit Suisse Initiates Coverage on Deciphera Pharmaceuticals ..
MT
2021DECIPHERA PHARMACEUTICALS : Barclays Adjusts Price Target on Deciphera Pharmaceuticals to ..
MT
2021DECIPHERA PHARMACEUTICALS : SVB Leerink Upgrades Deciphera Pharmaceuticals to Outperform F..
MT
2020DECIPHERA PHARMACEUTICALS : Stifel Nicolaus Starts Deciphera Pharmaceuticals at Buy With $..
MT
2020DECIPHERA PHARMACEUTICALS : SVB Leerink Lifts Deciphera Pharmaceuticals' Price Target to $..
MT
Upcoming event on DECIPHERA PHARMACEUTICALS, INC.